Deutsche Bank’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Deutsche Bank’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-15,957	Closed	-$1.55M	–	5622
2015 Q1	$1.55M	Sell	15,957 -35,683	-69%	-$3.78M	﹤0.01%	2617
2014 Q4	$4.79M	Buy	51,640 +20,179	+64%	+$1.59M	﹤0.01%	1992
2014 Q3	$2.16M	Buy	31,461 +21,947	+231%	+$1.57M	﹤0.01%	2471
2014 Q2	$997K	Sell	9,514 -32,561	-77%	-$2.77M	﹤0.01%	2947
2014 Q1	$3.49M	Buy	42,075 +6,922	+20%	+$640K	﹤0.01%	2056
2013 Q4	$2.27M	Sell	35,153 -7,494	-18%	-$445K	﹤0.01%	2220
2013 Q3	$2.7M	Buy	42,647 +19,250	+82%	+$948K	﹤0.01%	2272
2013 Q2	$980K	Buy	+23,397	New	+$1.07M	﹤0.01%	2719

Deutsche Bank's GEVA Position: Q2 2015 in Review

Deutsche Bank sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 15,957 shares — an estimated $1.55M sold.

Deutsche Bank first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $4.79M in Q4 2014. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

Deutsche Bank reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
Deutsche Bank sold 15,957 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $1.55M.
Deutsche Bank first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
Deutsche Bank's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $4.79M in Q4 2014.
0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Deutsche Bank's 13F filing for Q2 2015, filed 12 Aug 2015.